Active Filter(s):
Details:
These funds will be used notably for the development of a new generation of natural vaccines using exosomes to prevent SARS-CoV-2 infection, including the variants responsible for the severe form of Covid-19.
Lead Product(s): Exosomes-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $5.5 million Upfront Cash: Undisclosed
Deal Type: Funding March 08, 2022